Home LiteratureArticle Details
PMID: 19461667 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

The biology of ovarian cancer: new opportunities for translation.

Nature reviews. Cancer ·Vol. 9 ·No. 6 ·2009-06-00 ·Pages 415-28

Bast RC, Hennessy B, Mills GB

Abstract

Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.

MeSH Terms
Animals Antineoplastic Agents/pharmacology,therapeutic use Drug Design Female Humans Ovarian Neoplasms/drug therapy,genetics
Chemicals
Antineoplastic Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Bast Robert C
Departments of Experimental Therapeutics and Systems Biology, University of Texas M. D. Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, TX 77030, USA. rbast@mdanderson.org
Hennessy Bryan
Mills Gordon B
References (120)
120 references, click to expand
  1. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
    Cancer. 2006 Dec 1;107(11):2730-40 PMID: 17063503
  2. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.
    Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 PMID: 16849428
  3. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
    Mol Cancer. 2006 Oct 26;5(1):50 PMID: 17067392
  4. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
    Int J Cancer. 2008 Jan 1;122(1):91-9 PMID: 17893878
  5. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
    Gynecol Oncol. 2004 Dec;95(3):449-55 PMID: 15581945
  6. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
    J Biol Chem. 2004 Feb 27;279(9):7576-83 PMID: 14662759
  7. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
    Ann N Y Acad Sci. 2006 Dec;1091:270-81 PMID: 17341621
  8. Stress hormone-mediated invasion of ovarian cancer cells.
    Clin Cancer Res. 2006 Jan 15;12(2):369-75 PMID: 16428474
  9. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium.
    Mol Cancer Ther. 2006 Feb;5(2):382-90 PMID: 16505113
  10. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Lancet Oncol. 2009 Apr;10(4):327-40 PMID: 19282241
  11. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
    Blood. 2005 Nov 1;106(9):3150-9 PMID: 16014563
  12. Beyond chemotherapy: targeted therapies in ovarian cancer.
    Nat Rev Cancer. 2009 Mar;9(3):167-81 PMID: 19238149
  13. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
    Br J Cancer. 2001 Nov 2;85(9):1359-67 PMID: 11720475
  14. Significance of Fas receptor protein expression in epithelial ovarian cancer.
    Hum Pathol. 2005 Sep;36(9):971-6 PMID: 16153459
  15. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  16. Frequent microsatellite instability in epithelial borderline ovarian tumors.
    Cancer Res. 1996 Jun 1;56(11):2501-5 PMID: 8653685
  17. microRNAs exhibit high frequency genomic alterations in human cancer.
    Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 PMID: 16754881
  18. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
    Cancer Biol Ther. 2006 Dec;5(12):1708-13 PMID: 17106249
  19. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.
    Cancer Res. 2006 Sep 1;66(17):8404-12 PMID: 16951150
  20. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol. 2003 Oct 15;21(20):3814-25 PMID: 14551300
  21. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
    Clin Cancer Res. 2003 Feb;9(2):762-6 PMID: 12576447
  22. Aurora kinases as anticancer drug targets.
    Clin Cancer Res. 2008 Mar 15;14(6):1639-48 PMID: 18347165
  23. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
    Int J Gynecol Cancer. 2005 Sep-Oct;15(5):785-92 PMID: 16174225
  24. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Cancer. 2008 Apr 1;112(7):1489-502 PMID: 18286529
  25. In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.
    Cancer Res. 1997 Apr 1;57(7):1228-32 PMID: 9102203
  26. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.
    J Clin Oncol. 2005 Sep 1;23(25):5950-9 PMID: 16135466
  27. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Ann N Y Acad Sci. 2008 Sep;1138:136-45 PMID: 18837894
  28. Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
    Cancer Res. 2008 Jun 1;68(11):4311-20 PMID: 18519691
  29. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24 PMID: 16116079
  30. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer.
    Cancer Res. 2004 Aug 15;64(16):5535-8 PMID: 15313886
  31. A new small-molecule Stat3 inhibitor.
    Chem Biol. 2006 Nov;13(11):1123-4 PMID: 17113993
  32. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000 PMID: 12096084
  33. Targeted therapy for epithelial ovarian cancer: current status and future prospects.
    Int J Gynecol Cancer. 2003 Nov-Dec;13(6):701-34 PMID: 14675307
  34. Apoptosis in epithelial ovarian tumours Prognostic significance of clinical and histopathologic factors and its association with the immunohistochemical expression of apoptotic regulatory proteins (p53, bcl-2 and bax).
    Eur J Obstet Gynecol Reprod Biol. 2007 Jan;130(1):121-8 PMID: 16876311
  35. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
    Clin Cancer Res. 2007 Jun 1;13(11):3423-30 PMID: 17545551
  36. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
    Clin Cancer Res. 2004 Jun 1;10(11):3919-26 PMID: 15173101
  37. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells.
    Cancer Res. 2006 Mar 15;66(6):3006-14 PMID: 16540649
  38. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
    Am J Obstet Gynecol. 1992 Feb;166(2):676-84 PMID: 1536252
  39. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.
    J Biol Chem. 2004 Mar 5;279(10):9190-8 PMID: 14676194
  40. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
    N Engl J Med. 1983 Oct 13;309(15):883-7 PMID: 6310399
  41. Precursor lesions of ovarian epithelial malignancy.
    Histopathology. 2001 Feb;38(2):87-95 PMID: 11207821
  42. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Cancer Res. 2002 Feb 15;62(4):1087-92 PMID: 11861387
  43. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.
    Cancer Res. 2001 Apr 1;61(7):3194-9 PMID: 11306508
  44. Genetic analysis of early- versus late-stage ovarian tumors.
    Cancer Res. 2001 Aug 1;61(15):5895-904 PMID: 11479231
  45. Emerging role of RAB GTPases in cancer and human disease.
    Cancer Res. 2005 Apr 1;65(7):2516-9 PMID: 15805241
  46. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation.
    Cancer Res. 2001 Jun 15;61(12):4842-50 PMID: 11406561
  47. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors.
    Oncogene. 1995 Oct 5;11(7):1249-54 PMID: 7478544
  48. Early detection of ovarian cancer.
    Biomark Med. 2008 Jun;2(3):291-303 PMID: 20477415
  49. The epigenetics of ovarian cancer drug resistance and resensitization.
    Am J Obstet Gynecol. 2004 Nov;191(5):1552-72 PMID: 15547525
  50. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract.
    Nat Med. 2005 May;11(5):531-7 PMID: 15821746
  51. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Clin Cancer Res. 2004 May 15;10(10):3291-300 PMID: 15161682
  52. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
  53. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.
    Gynecol Oncol. 2006 Sep;102(3):425-8 PMID: 16797681
  54. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis.
    Mol Carcinog. 2007 Feb;46(2):130-43 PMID: 17131304
  55. Estrogen receptor expression is a common feature of ovarian borderline tumors.
    Gynecol Oncol. 1996 Feb;60(2):301-7 PMID: 8631556
  56. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors.
    J Clin Oncol. 1995 Aug;13(8):1912-21 PMID: 7543560
  57. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites.
    Clin Cancer Res. 2002 Apr;8(4):1108-14 PMID: 11948121
  58. Genetic analysis of benign, low-grade, and high-grade ovarian tumors.
    Cancer Res. 1995 Dec 15;55(24):6172-80 PMID: 8521410
  59. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
    Gynecol Oncol. 1994 Feb;52(2):232-6 PMID: 7508877
  60. Role of apoptotic regulators in human epithelial ovarian cancer.
    Cancer Biol Ther. 2007 Jul;6(7):1101-5 PMID: 17611399
  61. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.
    J Clin Oncol. 2007 Jun 1;25(16):2281-7 PMID: 17538174
  62. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    J Clin Oncol. 2003 Jan 15;21(2):283-90 PMID: 12525520
  63. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.
    Cancer Res. 2007 Jan 15;67(2):585-92 PMID: 17234767
  64. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.
    J Biol Chem. 2001 Jul 20;276(29):27371-5 PMID: 11369781
  65. Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells.
    Biol Chem. 2006 Jun;387(6):807-11 PMID: 16800744
  66. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    J Clin Oncol. 2008 Jan 1;26(1):20-5 PMID: 18165636
  67. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
    J Clin Endocrinol Metab. 1982 May;54(5):1051-5 PMID: 6895900
  68. Genital talc exposure and risk of ovarian cancer.
    Int J Cancer. 1999 May 5;81(3):351-6 PMID: 10209948
  69. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.
    Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41 PMID: 18178086
  70. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.
    J Natl Cancer Inst. 1998 Mar 18;90(6):447-54 PMID: 9521169
  71. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 PMID: 17077358
  72. A genetically defined model for human ovarian cancer.
    Cancer Res. 2004 Mar 1;64(5):1655-63 PMID: 14996724
  73. Resistance to therapy caused by intragenic deletion in BRCA2.
    Nature. 2008 Feb 28;451(7182):1111-5 PMID: 18264088
  74. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells.
    J Clin Invest. 2008 Dec;118(12):3917-29 PMID: 19033662
  75. Nuclear factor-kappaB in cancer development and progression.
    Nature. 2006 May 25;441(7092):431-6 PMID: 16724054
  76. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.
    PLoS One. 2009;4(4):e4992 PMID: 19352430
  77. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization.
    Am J Pathol. 1998 Oct;153(4):1249-56 PMID: 9777956
  78. The p53 tumor suppressor gene frequently is altered in gynecologic cancers.
    Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):246-52 PMID: 8296829
  79. Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
    J Clin Invest. 2006 Oct;116(10):2610-21 PMID: 17016557
  80. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
    Mol Pharmacol. 2007 Nov;72(5):1137-45 PMID: 17675586
  81. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3.
    J Biol Chem. 2008 Mar 21;283(12):8046-54 PMID: 18182388
  82. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance.
    Cell Cycle. 2009 Jan 1;8(1):158-66 PMID: 19158483
  83. Markedly elevated levels of vascular endothelial growth factor in malignant ascites.
    Ann Surg Oncol. 1999 Jun;6(4):373-8 PMID: 10379858
  84. The essential role of MEKK3 in TNF-induced NF-kappaB activation.
    Nat Immunol. 2001 Jul;2(7):620-4 PMID: 11429546
  85. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
    Cancer Res. 2005 Jan 15;65(2):465-72 PMID: 15695388
  86. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
    Cancer Res. 2002 Aug 15;62(16):4722-9 PMID: 12183431
  87. Induction of autophagy and inhibition of tumorigenesis by beclin 1.
    Nature. 1999 Dec 9;402(6762):672-6 PMID: 10604474
  88. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer.
    J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 PMID: 8360934
  89. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
    J Clin Oncol. 2002 Mar 15;20(6):1562-9 PMID: 11896105
  90. Proteins with whey-acidic-protein motifs and cancer.
    Lancet Oncol. 2006 Feb;7(2):167-74 PMID: 16455481
  91. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Clin Cancer Res. 2005 Sep 1;11(17):6116-26 PMID: 16144910
  92. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
    Nature. 2008 Feb 28;451(7182):1116-20 PMID: 18264087
  93. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
    Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31 PMID: 17088539
  94. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.
    Gynecol Oncol. 2006 Aug;102(2):140-4 PMID: 16790264
  95. Significance of E2F-1 overexpression in epithelial ovarian cancer.
    Int J Gynecol Cancer. 2008 May-Jun;18(3):492-8 PMID: 17692085
  96. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
    Gynecol Oncol. 2006 Oct;103(1):226-33 PMID: 16631235
  97. Critical evaluation of p53 as a prognostic marker in ovarian cancer.
    Expert Rev Mol Med. 2004 May 17;6(12):1-20 PMID: 15147608
  98. Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression.
    J Biol Chem. 2007 Feb 16;282(7):4924-4931 PMID: 17158885
  99. Regulation and function of IKK and IKK-related kinases.
    Sci STKE. 2006 Oct 17;2006(357):re13 PMID: 17047224
  100. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
    Cancer. 2007 Jan 15;109(2):332-40 PMID: 17154180
  101. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.
    Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7 PMID: 17060621
  102. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    J Natl Cancer Inst. 2006 Dec 6;98(23):1694-706 PMID: 17148771
  103. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer.
    Clin Cancer Res. 2006 Nov 15;12(22):6598-602 PMID: 17121877
  104. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
    Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10 PMID: 18395047
  105. Human tissue kallikreins: the cancer biomarker family.
    Cancer Lett. 2007 Apr 28;249(1):61-79 PMID: 17275179
  106. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
    Am J Obstet Gynecol. 1998 Apr;178(4):670-7 PMID: 9579428
  107. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
    Int J Gynecol Pathol. 2008 Apr;27(2):151-60 PMID: 18317228
  108. BRCA1 and BRCA2: 1994 and beyond.
    Nat Rev Cancer. 2004 Sep;4(9):665-76 PMID: 15343273
  109. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Cancer Treat Rev. 2009 May;35(3):262-71 PMID: 19117687
  110. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
    Clin Cancer Res. 2005 Aug 1;11(15):5539-48 PMID: 16061871
  111. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Clin Cancer Res. 2008 Aug 15;14(16):5198-208 PMID: 18698038
  112. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.
    J Biol Chem. 2004 Mar 5;279(10):9653-61 PMID: 14670967
  113. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation.
    J Natl Cancer Inst. 1992 Dec 2;84(23):1793-8 PMID: 1433368
  114. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
    Cancer Res. 2007 Jun 15;67(12):5840-50 PMID: 17575152
  115. Ovarian carcinoma diagnosis.
    Cancer. 2000 Nov 15;89(10):2068-75 PMID: 11066047
  116. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Cancer Gene Ther. 2002 Jul;9(7):553-66 PMID: 12082455
  117. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    N Engl J Med. 2006 Jan 5;354(1):34-43 PMID: 16394300
  118. BRCA2 mutations in primary breast and ovarian cancers.
    Nat Genet. 1996 Jun;13(2):238-40 PMID: 8640235
  119. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells.
    Oncogene. 2001 Nov 29;20(55):7925-34 PMID: 11753675
  120. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Cancer Res. 2007 Jan 1;67(1):281-8 PMID: 17210709
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2644
Email
rbast@mdanderson.org
Published
2009-06-00
Pages
415-28
Language
English
Region
England
NLM ID
101124168
PMCID
PMC2814299
Subset
IM
Grants
NCI NIH HHS · P30 CA016672 · United States
NCI NIH HHS · P50 CA098258 · United States
NCI NIH HHS · P50 CA083639 · United States
NCI NIH HHS · P50 CA083639-09 · United States
NCI NIH HHS · P50 CA 83639 · United States
External Links
PubMed source DOI: 10.1038/nrc2644 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2